Actively Recruiting
Screening for Hepatitis C in People Who Inject Drugs in Armenia-Colombia
Led by Asociación Colombiana de Hepatología · Updated on 2024-06-18
205
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatitis C virus infection is a leading cause of chronic hepatitis, cirrhosis, and liver cancer, especially prevalent among people who inject drugs (PWID). This observational study aims to determine the prevalence of hepatitis C virus (HCV) infection in PWID aged 18 to 65 in Armenia-Colombia by screening for HCV antibodies and confirming positive cases with viral load PCR. The study also seeks to support patients in accessing treatment and care, addressing a significant public health challenge where many HCV-positive individuals remain unaware of their status. The study will involve 205 PWID participants selected through a respondent-driven sampling method. Participants will undergo rapid HCV antibody testing, with those testing positive receiving confirmation via PCR viral load testing. This approach allows for a statistically valid sample and helps characterize the affected population. The study will facilitate linkage to care and support treatment access for participants. Participants will complete surveys and undergo diagnostic testing, including rapid antibody screening and PCR confirmation. The study will measure the prevalence of HCV antibodies and track the proportion of patients who gain access to treatment over a 10-month period. This observational research includes public health strategies to improve diagnosis and treatment access for PWID, with data collection focused on understanding and addressing HCV infection in this vulnerable group.
CONDITIONS
Brief Title
Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be between 18 and 65 years old.
- Have used injected psychoactive substances in the last six months.
- Reside in the city or metropolitan area of Armenia-Colombia for the last six months.
- Present an invitation coupon.
- Be a person with Colombian nationality or Venezuelan migrant population.
You will not qualify if you...
- Unable to answer the survey independently due to physical, cognitive, or substance use limitations.
- Currently in a state of consumption and unable to respond to the survey.
- Refuse to participate in the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 months
Participants are observed to determine the prevalence of hepatitis C through antibody testing and viral load confirmation.
1 visit for antibody testing and possible follow-up for viral load confirmation
Trial Site Locations
Total: 1 location
1
Colombian Association of Hepatology
Armenia, Quindío Department, Colombia, 050001
Actively Recruiting
Research Team
J
Javier Hernández Blanco, MD
D
Diana Chávez Bejarano, Bac
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here